- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04878549
Transcriptomic Responses for the Identification of Pathogens (TRiP)
A Multisite Evaluation of Functional Genomic Signatures for the Improved Diagnosis of Acute Undifferentiated Febrile Infections
Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions. Assessment of the host gene expression response to infection in endemic populations has demonstrated significant promise as a new approach to identifying patients with enteric fever and for potential in differentiating between other causes of AUFI. Signatures identified through new data analytic techniques could be developed into a point-of-care test for use in endemic settings.
In this multisite diagnostic evaluation study we will collect prospective clinical, laboratory and diagnostic data from two endemic settings to evaluate host gene expression signatures for detecting enteric fever and for determining the cause of AUFI in LMIC settings.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Farah Shahi
- Phone Number: 01142159522
- Email: f.shahi@sheffield.ac.uk
Study Contact Backup
- Name: Thomas Darton
- Email: t.darton@sheffield.ac.uk
Study Locations
-
-
-
Vellore, India
- Recruiting
- Christian Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
FEBRILE ADULTS- INCLUSION CRITERIA
- Age greater than or equal to 15 years and less than or equal to 45 years
- Participant is willing and they and/or an appropriate guardian/relative/representative is able to give informed consent for participation in the study and a follow-up (telephone) discussion at 14 days
Febrile illness without localising features (see 'exclusion criteria' and 'screening' sections) where fever is defined as:
- documented tympanic/rectal temperature of ≥ 38°C or an axillary/oral temperature of ≥ 37.8°C and
- Reported duration of fever 3-14 days
- They may have had recent exposure to antimicrobials.
FEBRILE ADULTS- EXCLUSION CRITERIA
- The participant may not enter the study if ANY of the following apply:
- Unable to provide informed consent and no next of kin is willing and able to provide informed consent.
Any history or clinical suspicion of:
- Rheumatological or connective tissue disorder (e.g. Rheumatoid arthritis)
- Autoimmune condition (e.g. Autoimmune Hepatitis)
- Malignancy
- Active treatment with immunomodulating medications, or for tuberculosis (pulmonary or extrapulmonary) or any other chronic infection.
- Pregnancy (breast feeding mothers will NOT be excluded)
- Hospitalisation within 4 weeks prior to current admission
- Vaccination within 4 weeks prior to current admission
- They live outside of the normal/local catchment area for each hospital site
- Localising signs or symptoms of infection sufficient to diagnose the likely cause of acute febrile illness and thus prevent it from being 'undifferentiated' (see Section 8.4 'Screening and Eligibility').
CONTROLS- INCLUSION CRITERIA
- Participant is willing and they are (and in 15-18 year olds, a guardian is) able to give informed consent for participation in the study
- Age greater than or equal to 15 years and less than or equal to 45 years
- They live outside of the normal/local catchment area for each hospital site
- Afebrile (as defined by no reported fever and temperature ≤ 38°C or an axillary/oral temperature of ≤ 37.8°C).
CONTROLS- EXCLUSION CRITERIA
- The participant may not enter the study if ANY of the following apply:
- Unable to provide informed consent and no next of kin (or parent/guardian in the case of a minor) is willing and able to provide informed consent.
Current treatment for or prior history, or clinical suspicion of:
- Rheumatological or connective tissue disorder
- Autoimmune condition
- Malignancy
- Active treatment for tuberculosis (pulmonary or extrapulmonary) or clinical suspicion of active tuberculosis. Previous completed treatment is not a reason for exclusion.
- Active treatment with immunomodulating medications or any other chronic infection.
- Pregnant (breast feeding mothers will NOT be excluded)
- Hospitalisation within 4 weeks of recruitment
- Vaccination within 4 weeks prior to recruitment
- Antimicrobial use within 4 weeks of recruitment
- They live outside of the normal/local catchment area for each hospital site
- Participant reports feeling more unwell than usual on the day of enrolment.
EXPLORATORY AIMS- PAEDIATRIC CRITERIA; INCLUSION CRITERIA
- Age greater than or equal to 2 years and less than 15 years
- As above for adult participants.
EXPLORATORY AIMS- PAEDIATRIC CRITERIA; EXCLUSION CRITERIA
- Parent/guardian is unwilling, and/or patient aged 8 to 14 years is unwilling to assent to provide informed consent.
- As above for adult participants.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Febrile Adults
1200 adult participants (15 to 45 years old) with a febrile illness without localising features and reported duration of 3-14 days.
|
This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever.
The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
|
Controls
400 afebrile, healthy adult participants (15 to 45 years old).
|
This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever.
The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
|
Febrile Children
400 child participants (2 to 14 years old) with a febrile illness without localising features and reported duration of 3-14 days.
This is an exploratory arm of the study.
|
This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever.
The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity (AUROC) of a diagnostic score derived from transcriptional responses by a 5-gene transcription signature (STAT1, SLAMF8, PSME2, WARS, ALDH1A1) in classifying patients with blood culture-confirmed enteric fever.
Time Frame: 2.5 years
|
Evaluate the performance of a host gene transcription signature for detecting enteric fever in adults presenting with acute undifferentiated fever (AUFI)
|
2.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with diagnosis confirmed by laboratory testing.
Time Frame: 2.5 years
|
Determine the frequency of other common causes of AUFI at each site.
|
2.5 years
|
Number of participants presenting with mild, moderate or severe illness by clinical diagnosis according to validated prognostic scores such as sepsis scoring systems.
Time Frame: 2.5 years
|
Assess the relationship between markers of clinical illness severity, likely infection cause and level of molecular perturbation.
|
2.5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Thomas Darton, University of Sheffield
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 157365
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fever
-
Meir Medical CenterCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
The Scientific and Technological Research Council...MonitorCROCompleted
-
Tongji HospitalRecruitingHFRS (Hemorrhagic Fever With Renal Syndrome)China
-
U.S. Army Medical Research and Development CommandBausch Health Americas, Inc.WithdrawnCrimean-Congo Hemorrhagic Fever | Lassa FeverGermany
-
Carina Mari ApariciWithdrawnFever of Unknown OriginUnited States
-
University Hospital, GrenobleCompletedFever of Unknown OriginFrance
-
Tongji HospitalUnknownFever of Unknown OriginChina
-
Beijing Friendship HospitalUnknown
Clinical Trials on 5-gene transcription signature
-
SkylineDxMedex15Active, not recruiting
-
Centre Hospitalier Universitaire de Saint EtienneCompletedGlomerulonephritis, IGAFrance
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingThyroid CancerFrance
-
Fondazione Italiana Linfomi - ETSRecruiting
-
Seoul National University HospitalActive, not recruitingAntibody-mediated Rejection | ABO Blood Type Incompatible Kidney TransplantationKorea, Republic of
-
ArthrogenUnknown
-
ArthrogenCentre for Human Drug Research (CHDR)UnknownArthritis, Rheumatoid | Osteo ArthritisNetherlands
-
Tocagen Inc.CompletedGlioblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic OligodendrogliomaUnited States
-
University Hospital, CaenThong DAO; Annie BOREL-DERLON; Nathalie GANNE-CARRIE; Pierre NAHON; Sylvie ChevretCompletedAlcoholic or Viral C Compensated CirrhosisFrance
-
University Hospital, GhentCompleted